{"id":15300,"date":"2023-08-10T22:42:00","date_gmt":"2023-08-10T14:42:00","guid":{"rendered":"https:\/\/flcube.com\/?p=15300"},"modified":"2024-11-27T22:48:09","modified_gmt":"2024-11-27T14:48:09","slug":"denali-therapeutics-and-takeda-halt-development-of-alzheimers-drug-candidate-tak-920-dnl919","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=15300","title":{"rendered":"Denali Therapeutics and Takeda Halt Development of Alzheimer\u2019s Drug Candidate TAK-920\/DNL919"},"content":{"rendered":"\n

US-based biopharmaceutical company Denali Therapeutics Inc., (NASDAQ: DNLI<\/a>) has announced in its Q2 2023 financial report that, in mutual agreement with development partner Takeda Pharmaceutical Co., Ltd (NYSE: TAK<\/a>), the decision has been made to cease development of the Alzheimer’s drug candidate TAK-920\/DNL919. This strategic decision was influenced by data from a Phase I trial and the rapidly evolving treatment landscape for Alzheimer’s disease.<\/p>\n\n\n\n

Background on the Partnership and Drug Candidate<\/strong>
Contrasting with recently approved amyloid-targeted Alzheimer’s drugs, DNL919 is an Antibody Transport Vehicle (ATV)-enabled TREM2 agonist designed to enhance microglial function. The two companies initially partnered in 2018 to explore three different targets for neurodegenerative disorders and established a full collaboration on DNL919 in 2021.<\/p>\n\n\n\n

Phase I Data and Decision Factors<\/strong>
According to sources, Phase I data demonstrated the molecule\u2019s \u201crobust target engagement and effects on microglial biomarkers\u201d. However, safety signals indicated \u201cmoderate, reversible hematologic effects\u201d, suggesting that the drug would likely have \u201ca narrow therapeutic window for the Alzheimer\u2019s disease patient population\u201d, specific to the properties of DNL919 and TREM2 biology.<\/p>\n\n\n\n

Refocusing Efforts on Backup Molecules and Combination Therapies<\/strong>
The two firms will continue their work in the field, redirecting efforts towards preclinical back-up molecules and exploring potential combination therapies. This shift comes in light of recent new drug approvals in Alzheimer’s disease, hinting at a possible future strategy involving an amyloid-targeted combination approach.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

US-based biopharmaceutical company Denali Therapeutics Inc., (NASDAQ: DNLI) has announced in its Q2 2023 financial…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[29,1522,27,1521,874,345],"class_list":["post-15300","post","type-post","status-publish","format-standard","hentry","category-company","tag-combination-therapy","tag-denali-therapeutics","tag-finanical-reports","tag-nasdaq-dnli","tag-nyse-tak","tag-takeda"],"yoast_head":"\nDenali Therapeutics and Takeda Halt Development of Alzheimer\u2019s Drug Candidate TAK-920\/DNL919 - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based biopharmaceutical company Denali Therapeutics Inc., (NASDAQ: DNLI) has announced in its Q2 2023 financial report that, in mutual agreement with development partner Takeda Pharmaceutical Co., Ltd (NYSE: TAK), the decision has been made to cease development of the Alzheimer\u2019s drug candidate TAK-920\/DNL919. This strategic decision was influenced by data from a Phase I trial and the rapidly evolving treatment landscape for Alzheimer's disease.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=15300\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Denali Therapeutics and Takeda Halt Development of Alzheimer\u2019s Drug Candidate TAK-920\/DNL919\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=15300\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-10T14:42:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-27T14:48:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15300#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15300\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Denali Therapeutics and Takeda Halt Development of Alzheimer\u2019s Drug Candidate TAK-920\\\/DNL919\",\"datePublished\":\"2023-08-10T14:42:00+00:00\",\"dateModified\":\"2024-11-27T14:48:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15300\"},\"wordCount\":248,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Combination therapy\",\"Denali Therapeutics\",\"Finanical Reports\",\"NASDAQ: DNLI\",\"NYSE: TAK\",\"Takeda\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15300#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15300\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=15300\",\"name\":\"Denali Therapeutics and Takeda Halt Development of Alzheimer\u2019s Drug Candidate TAK-920\\\/DNL919 - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-08-10T14:42:00+00:00\",\"dateModified\":\"2024-11-27T14:48:09+00:00\",\"description\":\"US-based biopharmaceutical company Denali Therapeutics Inc., (NASDAQ: DNLI) has announced in its Q2 2023 financial report that, in mutual agreement with development partner Takeda Pharmaceutical Co., Ltd (NYSE: TAK), the decision has been made to cease development of the Alzheimer\u2019s drug candidate TAK-920\\\/DNL919. This strategic decision was influenced by data from a Phase I trial and the rapidly evolving treatment landscape for Alzheimer's disease.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15300#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15300\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15300#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Denali Therapeutics and Takeda Halt Development of Alzheimer\u2019s Drug Candidate TAK-920\\\/DNL919\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Denali Therapeutics and Takeda Halt Development of Alzheimer\u2019s Drug Candidate TAK-920\/DNL919 - Insight, China's Pharmaceutical Industry","description":"US-based biopharmaceutical company Denali Therapeutics Inc., (NASDAQ: DNLI) has announced in its Q2 2023 financial report that, in mutual agreement with development partner Takeda Pharmaceutical Co., Ltd (NYSE: TAK), the decision has been made to cease development of the Alzheimer\u2019s drug candidate TAK-920\/DNL919. This strategic decision was influenced by data from a Phase I trial and the rapidly evolving treatment landscape for Alzheimer's disease.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=15300","og_locale":"en_US","og_type":"article","og_title":"Denali Therapeutics and Takeda Halt Development of Alzheimer\u2019s Drug Candidate TAK-920\/DNL919","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=15300","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-08-10T14:42:00+00:00","article_modified_time":"2024-11-27T14:48:09+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=15300#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=15300"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Denali Therapeutics and Takeda Halt Development of Alzheimer\u2019s Drug Candidate TAK-920\/DNL919","datePublished":"2023-08-10T14:42:00+00:00","dateModified":"2024-11-27T14:48:09+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=15300"},"wordCount":248,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Combination therapy","Denali Therapeutics","Finanical Reports","NASDAQ: DNLI","NYSE: TAK","Takeda"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=15300#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=15300","url":"https:\/\/flcube.com\/?p=15300","name":"Denali Therapeutics and Takeda Halt Development of Alzheimer\u2019s Drug Candidate TAK-920\/DNL919 - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-08-10T14:42:00+00:00","dateModified":"2024-11-27T14:48:09+00:00","description":"US-based biopharmaceutical company Denali Therapeutics Inc., (NASDAQ: DNLI) has announced in its Q2 2023 financial report that, in mutual agreement with development partner Takeda Pharmaceutical Co., Ltd (NYSE: TAK), the decision has been made to cease development of the Alzheimer\u2019s drug candidate TAK-920\/DNL919. This strategic decision was influenced by data from a Phase I trial and the rapidly evolving treatment landscape for Alzheimer's disease.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=15300#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=15300"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=15300#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Denali Therapeutics and Takeda Halt Development of Alzheimer\u2019s Drug Candidate TAK-920\/DNL919"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15300","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15300"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15300\/revisions"}],"predecessor-version":[{"id":15302,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15300\/revisions\/15302"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15300"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15300"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15300"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}